Your browser doesn't support javascript.
loading
Virus-like structures for combination antigen protein mRNA vaccination.
Zhang, Jingjing; Li, Yanmei; Zeng, Fengyuan; Mu, Changyong; Liu, Change; Wang, Lichun; Peng, Xiaowu; He, Liping; Su, Yanrui; Li, Hongbing; Wang, An; Feng, Lin; Gao, Dongxiu; Zhang, Zhixiao; Xu, Gang; Wang, Yixuan; Yue, Rong; Si, Junbo; Zheng, Lichun; Zhang, Xiong; He, Fuyun; Yi, Hongkun; Tang, Zhongshu; Li, Gaocan; Ma, Kaili; Li, Qihan.
Afiliação
  • Zhang J; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Li Y; Shandong WeigaoLitong Biological Products Co., Ltd, Weihai, China.
  • Zeng F; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Mu C; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Liu C; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Wang L; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Peng X; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • He L; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Su Y; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Li H; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Wang A; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Feng L; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Gao D; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Zhang Z; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Xu G; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Wang Y; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Yue R; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Si J; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Zheng L; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Zhang X; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • He F; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Yi H; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Tang Z; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Li G; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Ma K; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China.
  • Li Q; Weirui Biotechnology (Kunming) Co., Ltd, Ciba Biotechnology Innovation Center, Kunming, China. mklpumc@gmail.com.
Nat Nanotechnol ; 19(8): 1224-1233, 2024 Aug.
Article em En | MEDLINE | ID: mdl-38802667
ABSTRACT
Improved vaccination requires better delivery of antigens and activation of the natural immune response. Here we report a lipid nanoparticle system with the capacity to carry antigens, including mRNA and proteins, which is formed into a virus-like structure by surface decoration with spike proteins, demonstrating application against SARS-CoV-2 variants. The strategy uses S1 protein from Omicron BA.1 on the surface to deliver mRNA of S1 protein from XBB.1. The virus-like particle enables specific augmentation of mRNAs expressed in human respiratory epithelial cells and macrophages via the interaction the surface S1 protein with ACE2 or DC-SIGN receptors. Activation of macrophages and dendritic cells is demonstrated by the same receptor binding. The combination of protein and mRNA increases the antibody response in BALB/c mice compared with mRNA and protein vaccines alone. Our exploration of the mechanism of this robust immunity suggests it might involve cross-presentation to diverse subsets of dendritic cells ranging from activated innate immune signals to adaptive immune signals.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células Dendríticas / Glicoproteína da Espícula de Coronavírus / Vacinas contra COVID-19 / SARS-CoV-2 / Camundongos Endogâmicos BALB C Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células Dendríticas / Glicoproteína da Espícula de Coronavírus / Vacinas contra COVID-19 / SARS-CoV-2 / Camundongos Endogâmicos BALB C Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article